Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
Onconetix, Inc., a pharmaceutical company with a market capitalization of just $490,000, is facing potential delisting from The Nasdaq Stock Market LLC due to its inability to maintain the minimum bid price required by Nasdaq’s rules. According to InvestingPro data, the company’s stock currently trades at $0.06 per share, and its financial health score is rated as WEAK. The company, which specializes in pharmaceutical preparations and is based in Cincinnati, Ohio, has been notified that its common stock did not meet the minimum bid price of $1.00 per share over a specified period.
The Nasdaq notification, dated April 14, 2025, indicated that Onconetix’s stock had closed at a bid price of $0.10 or less for ten consecutive trading days. The stock has lost over 90% of its value year-to-date, falling from its 52-week high of $21.40. This situation triggers a provision under Nasdaq Listing Rule 5810(c)(3)(A)(iii), which could lead to the suspension of trading and eventual delisting of the company’s securities.
Onconetix plans to request a hearing before the Nasdaq Hearings Panel to appeal the decision and seek continued listing on the exchange. InvestingPro data reveals concerning financial metrics, including a negative EBITDA of $13.1 million and a critically low current ratio of 0.06, indicating significant liquidity challenges. This request will temporarily halt the suspension of trading and delisting process until the Panel reaches a decision. However, there is no guarantee that the Panel will rule in favor of Onconetix, and the company’s securities may still face delisting if a favorable outcome is not achieved.
In a related event, Onconetix’s board of directors has decided to postpone the 2025 annual meeting of shareholders, which was initially scheduled for June 4, 2025. The new date for the Annual Meeting has not been announced, but the company will set a new record date for shareholder notice and voting, and will establish a deadline for shareholder proposals as per the company’s by-laws and the Securities and Exchange Act of 1934.
This information is based on a press release statement filed with the Securities and Exchange Commission on April 18, 2025. The company, formerly known as Blue Water Biotech, Inc., and Blue Water Vaccines Inc., has undergone name changes in the past, with the most recent change occurring on April 24, 2023. The potential delisting raises concerns for Onconetix’s future on the public market and its ability to meet Nasdaq’s continued listing standards. For a comprehensive analysis of Onconetix’s financial health and future prospects, investors can access the detailed Pro Research Report available on InvestingPro, which provides expert insights and key metrics for over 1,400 US stocks.
In other recent news, Onconetix, Inc. has announced a potential merger with Ocuvex Therapeutics, Inc. through a non-binding Letter of Intent. This merger would allow Onconetix to acquire all equity interests of Ocuvex, with Ocuvex equity holders owning approximately 90% of the combined entity. The merger aims to diversify Onconetix’s portfolio by incorporating Ocuvex’s ophthalmic assets. Additionally, Onconetix recently presented clinical data for its prostate cancer diagnostic tool, Proclarix, at the European Association of Urology congress, highlighting its effectiveness in reducing unnecessary biopsies. In terms of leadership changes, James Sapirstein has been appointed as the Executive Chairman, succeeding Dr. Ralph Schiess. Furthermore, Oncopeptides, a separate company, reported a 35% increase in European sales for Q4 2024, driven by market expansions in Spain and Germany, and is targeting cash flow positivity by the end of 2026. These developments reflect ongoing strategic efforts by Onconetix and its industry peers to expand market presence and enhance shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.